Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Albireo Pharma, Inc.    ALBO

ALBIREO PHARMA, INC.

(ALBO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis

share with twitter share with LinkedIn share with facebook
10/16/2017 | 09:01am EDT

BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it will host a Key Opinion Leader (KOL) breakfast meeting focused on the topic of progressive familial intrahepatic cholestasis (PFIC), a pediatric orphan liver disease, at the Lotte Palace Hotel in New York City on Wednesday, October 25, 2017, from 8:00 a.m. to 9:30 a.m. ET.

The meeting will feature a presentation by Ekkehard Sturm, M.D., Ph.D., pediatric hepatologist and the head of pediatric gastroenterology-hepatology, liver and intestinal transplantation at Children’s Hospital, University of Tuebingen in Germany. Dr. Sturm will address the current therapeutic landscape and unmet medical need in the treatment of children with PFIC and will be available to answer questions following the meeting.

In addition, Albireo management will provide an overview of Albireo’s planned Phase 3 clinical program for A4250 in children with PFIC.

Dr. Sturm serves as the pediatric coordinator of the European Reference Network RARE LIVER. He has authored or co-authored more than 50 original manuscripts, reviews and case reports published in such journals as Journal of Pediatric Surgery, Pediatric Transplantation, European Journal of Pediatrics, The Lancet, Journal of Hepatology and HEPATOLOGY. In addition, he has authored six textbook chapters on topics such as PFIC, disorders of the intrahepatic bile ducts, and living donation for liver transplantation. Dr. Sturm is a member of the American Association for the Study of Liver Diseases, the German Society for Pediatric Gastroenterology and Nutrition, the German Society of Pediatrics and Adolescent Medicine, the Dutch Society for Pediatrics and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. He holds advanced degrees from Hannover Medical School in Germany and The University Medical Center Groningen in the Netherlands and trained as a post-doctoral research fellow at Yale University.

To register to attend the event, contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com.  Advanced registration is required, as space is limited.

A live and archived webcast of the event will be available on the Investors page of Albireo’s website at http://ir.albireopharma.com.  To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. The archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo's website for at least two weeks following the event.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com

Source: Albireo Pharma, Inc.

Primary Logo

© GlobeNewswire 2017

share with twitter share with LinkedIn share with facebook
All news about ALBIREO PHARMA, INC.
10/26ALBIREO PHARMA : Announces Presentations at NASPGHAN 2020 Annual Meeting
AQ
10/23Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting
GL
10/23ALBIREO PHARMA : Announces Presentations at NASPGHAN 2020 Annual Meeting
AQ
10/15ALBIREO PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/06ALBIREO PHARMA : Recognizes PFIC Awareness Day 2020
AQ
10/05ALBIREO PHARMA : Reports Inducement Grant under Nasdaq Listing Rule 5635
AQ
10/05ALBIREO PHARMA : Recognizes PFIC Awareness Day 2020
AQ
10/05Albireo Recognizes PFIC Awareness Day 2020
GL
10/02Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
10/02ALBIREO PHARMA : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
More news
Financials (USD)
Sales 2020 7,50 M - -
Net income 2020 -105 M - -
Net cash 2020 279 M - -
P/E ratio 2020 -4,95x
Yield 2020 -
Capitalization 620 M 620 M -
EV / Sales 2020 45,5x
EV / Sales 2021 27,2x
Nbr of Employees 55
Free-Float 80,1%
Chart ALBIREO PHARMA, INC.
Duration : Period :
Albireo Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALBIREO PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 69,38 $
Last Close Price 32,65 $
Spread / Highest target 148%
Spread / Average Target 112%
Spread / Lowest Target 89,9%
EPS Revisions
Managers
NameTitle
Ronald H. W. Cooper President, Chief Executive Officer & Director
David John Chiswell Chairman
Simon John Harford Chief Financial Officer & Treasurer
Jan Peter Mattsson Chief Scientific Officer, Managing Director-Sweden
Patrick Taylor Horn Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALBIREO PHARMA, INC.29.90%627
GILEAD SCIENCES, INC.-7.73%75 173
REGENERON PHARMACEUTICALS56.00%61 638
VERTEX PHARMACEUTICALS-5.39%53 956
WUXI APPTEC CO., LTD.64.97%37 810
BEIGENE, LTD.81.76%27 304